Skip to content

Time Prediction and Cerebellum: Magnetic Transcranial Stimulation (TMS) in Healthy Volunteers

Effects of the Magnetic Transcranial Stimulation (TMS) in Healthy Volunteers

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04300946
Enrollment
48
Registered
2020-03-09
Start date
2021-10-10
Completion date
2025-10-01
Last updated
2025-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Brief summary

The aim of the study is to check the role of the cerebellum in time prediction in healthy volunteers, by means of magnetic transcranial stimulation targeted on the cerebellum, and recording of behavioural measures indexing time prediction

Interventions

DEVICETMS targeted on the cerebellum

Impact on EEG performance (preparation wave in temporal tasks) of cerebellar stimulation by MSD in healthy subjects. The contrast between the post-stimulation effects of verrum stimulation and placebo stimulation will indicate the magnitude of the effect and will allow us to optimize the type of protocol that may be useful in schizophrenia.

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Participant, male or female, between 18 and 60 years old * Subject affiliated to a social health insurance scheme (beneficiary or entitled person) * Subject who has dated and signed an informed consent form * For a woman of childbearing age, negative pregnancy test and effective contraception throughout the study

Exclusion criteria

* \- Participant with substance use disorders (as defined by DSM-V) * Participants taking benzodiazepines and related substances (in the period before inclusion, for a duration equivalent to 5 half-lives of the product), cannabis (in the 2 months before inclusion) or hallucinogenic substances (in the period before inclusion, for a duration equivalent to 5 half-lives of the product). * Participant with neurological pathology or sequelae * Participant with Attention Deficit Hyperactivity Disorder (ADHD) * Participant with a borderline personality disorder * Participant with disabling sensory impairments, including visual acuity (corrected, if applicable) \< 0.8 (due to use of visual material) (Freiburg Vision Test, Bach 1996) * Participant deprived of liberty or subject to the safeguard of justice * Participant under guardianship or curatorship * Participant in a period of exclusion defined by another clinical study or participant in a study that may impact on research results * Pregnant or breastfeeding woman * Subject with a contraindication to performing an MRI or TMS: presence of non-removable ferromagnetic body, prosthesis, pacemaker, medication delivered by an implanted pump, vascular clip or stent, heart valve or ventricular lead, certain intracerebral clips, cochlear implants, history of epilepsy, skin pathology at the point of contact with the electrodes. * Subject with a history of major neurological or psychiatric illness with current psychotropic medication (i.e., antidepressant, thyroid regulator, antipsychotic, benzodiazepine and related drugs, or hypnotic).

Design outcomes

Primary

MeasureTime frameDescription
EEG index of time expectation40 minutesCNV

Countries

France

Contacts

Primary ContactAnne Giersch
giersch@unistra.fr000333

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026